

Donald V. Jablonski, M.D.
1812 North Mills Avenue
Orlando, FL 32803

Education:

1953 – 1956 University of Michigan
Ann Arbor, Michigan

1956 – 1960 M.D. at Wayne Sate University
Detroit, Michigan

Post-Doctoral Training:

1960 – 1961 Internship at Detroit Receiving Hospital
Detroit, Michigan

1963- 1965 Resident in Surgery at Detroit General Hospital
Detroit, Michigan

1965 – 1968 Resident in Urology at Wayne Sate University
Affiliated Hospital
Detroit, Michigan

Membership:

Diplomat American Board of Urology
Orange County Medial Society
Southeastern Section of the American Urological Association
Florida Urological Society
American Medical Association
American Urological Association
American College of Surgeons, Fellow
Society for Pediatric Urology

Medical Licensure: Florida #ME-0014504

Position: Winter Park Urology Associates
1970 – Present

Academic Appointments:

1968 – 1970 Assistant Professor & Transplant Surgeon
Department on Urology
Wayne State University, College of Medicine

Present Associate Clinical Professor of Surgery
University of Florida
Division of Urology

Present Clinical Assistant Professor
Florida State University School of Medicine
Department of Clinical Sciences

Hospital Appointments:

Florida Hospital, Active
Winter Park Memorial Hospital, Active
Veterans Administration Hospital, Consultant
Shands Teaching Hospital, Consultant
Florida Hospital, President Medical Staff, 1985 – 1986

Research:

1996 – 2000 “A Randomized, Double-Blind, Comparative Trial of a Study Drug Versus Placebo in Patients with Early Prostate Cancer”

1997 – 2000 “A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of Study Drug 0.5 Mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia”

1997 – 1998 “A Phase III Efficacy and Safety Study Comparing Escalating Doses of Study Drug to 5 mg or 6 mg Doses of Study Drug or Placebo in the Treatment of Male Erectile Dysfunction”

1997 – 1998 “A Study to Evaluate the Impact of Study Drug on Treatment Satisfaction”

1998 – 1999 “A Phase III, Long-Term, Open-Label, Flexible Dose, and Safety Extension Study of Study Drug in the Treatment of Male Erectile Dysfunction”

1999 – 2001 “A Phase III at Home Use Study Evaluating the Efficacy and Safety of Escalating Doses of Study Drug 2, 3, and 4 mg in the Treatment with Erectile Dysfunction”

1999 – 2001 “A Study to Evaluate the Efficacy and Safety of a Study Drug Versus Placebo in

Subjects with Overactive Bladder”

- 1999 – 2001 “A Phase III, Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of a Controlled Release Study Drug Versus A Study Drug in the Treatment of Subjects with Overactive Bladder”
- 1999 – 2000 “A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study Comparing the Safety, Tolerance, and Efficacy of a Study Drug in Patients with Detrusor Hyperreflexia”
- 2000 – 2001 “A Randomized, Double-Blind, Multi-Centre, Fixed Dose, Parallel-Group Twelve Month Study to Investigate the Safety and Tolerability of a Study Drug in the Treatment of Patients with Erectile Dysfunction”
- 2000 – 2003 “A phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of Study Drug for the Treatment of Hot Flashes Following Surgical or Chemical Castration of Prostate Cancer Patients and Its Impact on the Quality of Life in These Patients”
- 2000 – 2001 “A Phase IV, Open-label, Multi-Center, Large Community Based Study with an Eight Week Treatment Period to Evaluate the Satisfaction and Experience with Replacement Therapy”
- 2000 - 2001 “A Phase IV, Open-Label, Multicenter, Community-Based Trial of Study Drug for the Treatment of Urogenital Symptoms in Postmenopausal Women”
- 2000 - 2001 “A Patient Acceptability Study of a Once-Daily Formulation of Study Drug. A Phase IIIB, Open-Label, Single-Arm Trial in Adult Patients With Overactive Bladder and Symptoms of Urinary Frequency, Urgency, and/or Urge Incontinence.”
- 2001 – 2001 “A Multicenter Trial of Induction and 6 Courses of 3 Week Maintenance With BCG Versus BCG Plus Interferon Alfa-2B (Intron A) In Superficial Bladder Cancer”
- 2001 – 2001 “A Multi-center, Multinational Open Clinical Study to Explore Relationships between Genotypic (from DNA) and Serologic (from serum) Findings and Phenotypic Manifestations in a Large Cohort of Participants”
- 2001 – 2002 “Prospective, Randomized, Double-Blind Multi-Center, Fixed Dose, Parallel-Group Twelve Month Extension of Study XXXXX to Investigate the Safety and Tolerability of the Study Drug in the Treatment of Patients with Erectile Dysfunction over a Total Exposure Time of 24 Months”

- 2001 – 2002 “A Phase III, Double-Blind, Randomized, Parallel Study Evaluating the Safety and Efficacy of Study Drug in the Treatment of Male Erectile Dysfunction”
- 2001 – 2003 “Double-Blind, Placebo Controlled Study of Sustained Release Study Drug in Subjects with Symptoms of Overactive Bladder of Urgency, Frequency and Urinary Incontinence”
- 2001 – 2002 “An Investigation Of The NMP22 Point of Care (POC) Device As An Aid In The Monitoring Of Bladder Cancer Patients.”
- 2001 – 2002 “An Investigation Of The NMP22 Point Of Care (POC) Device As An Aid In The Screening Of Patients At Risk For Bladder Cancer.”
- 2002-2003 “An Open-Label, Multicenter, Multinational Study to Determine the Safety and Efficacy of XXXXX Oral Solution in Children with Symptoms of Urge Urinary Incontinence Suggestive of Detrusor Instability”
- 2001-2004 “A Mutlicenter, Phase IIB, Four Arm, Dose-Finding, Randomized, Placebo-Controlled Study to Determine the Long Term Prostate Cancer Chemoprevention Efficacy and Safety of 20mg, 40mg & 60mg Daily Study Drug in Men with High Grade Prostate Intraepithelial Neoplasia (PIN)”
- 2002-2002 “A Randomized, Double-Blind, Parallel Group, Multicenter Study to Investigate the Time to Onset of Action of 20mg of Study Drug Compared to Placebo in Males with Erectile Dysfunction”
- 2003-2003 “To Generate Performance and Labeling Claims of the Advia Centaur BNP Method: for the Quantitative in vitro Determination of B-type Natriuretic Peptide (BNP) in human plasma; as an aid in the Diagnosis of Congestive Heart Failure (CHF)” (Blood Draw Study)
- 2003-2003 “A Double-Blind, Placebo-Controlled, Randomized US/Latin America Study to Evaluate the Effect of Study Drug Prolonged Release on Nocturia in Patients with Symptoms of Overactive Bladder (OAB)”
- 2003-Present “A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Study Drug 0.5mg Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer”
- 2003-2004 “A Double-Blind, Placebo-Controlled Study of Frequency and Urgency Using Study Drug 20mg Tablets, Twice Daily, For 12 Weeks Followed by a 6-Month Open-Label Treatment Phase in Patients with Overactive Bladder”

2003-2004	“A Multicenter, Open Label, Flexible Dose Study to Investigate the Use Patterns of Viagra® (sildenafil citrate) And The Ability of Investigators To Further Optimize Subject Satisfaction With Viagra® Through Customized Instruction”
2003- 2004	“Open-Label Study of the Efficacy and Safety of 5mg and 10mg Study Drug in Patients with Overactive Bladder Symptoms”
2003-2004	“An Open-Label Study to Evaluate the Efficacy and Safety of Study Drug Administered ‘On Demand’ to Men of Various Populations with Erectile Dysfunction”
2003-present	“A Phase 3, Parallel Group, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Study Drug Sustained Release in Subjects with Overactive Bladder Syndrome”
2003-present	“A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of study Drug for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy”
2004-present	“Study of XXXX in Women of Different Demographic Characteristics and Co-morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety”
2004-2004	“REALISE: Real Life Safety and Efficacy of Levitra®”
2004-present	“A Study to Compare the Safety and Efficacy of Once Daily Study Drug Versus Twice Daily Study Drug in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis”
2004-present	“A Double-Blind, Randomized, Placebo-Controlled Trial of Elmiron® For The Treatment of Chronic, Non-Bacterial Prostatitis”
2004-present	“A Randomized, Double-Blind, Crossover Study to Evaluate the Duration of Erection following Study Drug 10mg Administration for 4 Weeks in a Fixed-Dose Regimen Compared to Placebo In Males with ED”
2004-present	“An Open-Label, Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5 and 10mg Study Drug in Patients Who Wish to Switch from Detrol LA® for the Treatment of Overactive Bladder Symptoms”
2004-present	“Prospective, Observational Registry and Patient Survey of the Management of Men with Symptomatic Benign Prostatic Hyperplasia”

- 2005-present “A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdrawal Effects of Chronic Daily and As Needed Dosing with Study Drug in the Treatment of Premature Ejaculation”
- 2005-present “A Multicenter, 2 Week, Double-Blind Study of XXXX 60mg QD Modified Release Capsules and Placebo Given Once Daily In The Morning or In The Evening In Patients with Overactive Bladder”
- 2005-present “A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of XXXX for the Prevention of Prostate Cancer in Men with High Grade Prostate Intraepithelial Neoplasia”

Updated: 1/2005